[CAS NO. 69659-80-9] Tanshinone IIA sulfonate sodium

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [69659-80-9]

Catalog

SLK-S3766

Brand

Selleck

CAS

69659-80-9

DESCRIPTION [69659-80-9]

Overview

MDL	MFCD09028094
Molecular Weight	396.39
Molecular Formula	C19H17O6S.Na
SMILES	CC=1C2=C(C=3C(=C4C(=CC3)C(C)(C)CCC4)C(=O)C2=O)OC1S(=O)(=O)O.[Na]

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	2.5228 mL	12.6138 mL	25.2277 mL
5 mM	0.5046 mL	2.5228 mL	5.0455 mL
10 mM	0.2523 mL	1.2614 mL	2.5228 mL
50 mM	0.0505 mL	0.2523 mL	0.5046 mL

Description

Sodium tanshinone IIA sulfonate (STS) is a water-soluble derivative of tanshinone IIA isolated as the main pharmacologically active natural compound from a traditional Chinese herbal medicine, the dried root of Salvia miltiorrhiza Bunge known as Danshen. Sodium tanshinone IIA sulfonate (STS) is a potent negative allosteric modulator of the . Sodium tanshinone IIA sulfonate (STS) inhibits the activity of and through store-operated Ca2+ channels (SOCC) via downregulating the expression of transient receptor potential canonical proteins (TRPC).

Targets

SOCE ^[2]	P2X7 ^[4]	CYP3A4 ^[1] (Cell-free assay)
		6.377 μM

In vitro

Sodium tanshinone IIA sulfonate (STS) inhibits the activity of CYP3A4 in a dose-dependent manner in the HLMs and CYP3A4 isoform. Other CYP isoforms, including CYP1A2, CYP2A6, CYP2C9, CYP2D6, CYP2E1, and CYP2C19, show minimal or no effect on the metabolism of STS. Thus, STS is a potent inhibitor for CYP3A4. STS upregulates the protein expression of Bcl-2 and downregulates the proteins expression of Bax and Caspase-3. Sodium tanshinone IIA sulfonate (STS) inhibits store-operated Ca2+ entry (SOCE) through store-operated Ca2+ channels (SOCC) via downregulating the expression of transient receptor potential canonical proteins (TRPC). STS treatment can effectively prevent the hypoxia-mediated inhibition of the PKG-PPAR-γ signaling axis in rat distal pulmonary arterial smooth muscle cells (PASMCs) and distal pulmonary arteries. It can also prevent hypoxia-mediated increases in intracellular calcium homeostasis and cell proliferation, by targeting and restoring the hypoxia-inhibited PKG-PPAR-γ signaling pathway in PASMCs.

References

[1] Chen D, et al. Xenobiotica. 2016, 46(12):1085-1092.
[2] Qing-Qing Xu, et al. BioMed Research International. 2016.
[3] Jiang Q, et al. Am J Physiol Cell Physiol. 2016, 311(1):C136-49.
[4] M Kaiser, et al. J Pharmacol Exp Ther . 2014 Sep;350(3):531-42.

Synonyms

Phenanthro[1,2-b]furan-2-sulfonic acid, 6,7,8,9,10,11-hexahydro-1,6,6-trimethyl-10,11-dioxo-, sodium salt (1:1)

Phenanthro[1,2-b]furan-2-sulfonic acid, 6,7,8,9,10,11-hexahydro-1,6,6-trimethyl-10,11-dioxo-, sodium salt

DS 201

Sodium tanshinone IIA sulfonate

Tanshinone IIA sodium sulfonate

Sulfotanshinone sodium II-A